Therapeutic Efficacy of Pyronaridine-artesunate (Pyramax) Against Uncomplicated Plasmodium Falciparum Infection at Hamusit Health Centre, Northwest Ethiopia

Overview

Journal Malar J

Publisher Biomed Central

Specialty Tropical Medicine

Date 2023 Jun 17

PMID 37330475

Authors

Mihreteab Alebachew

Woyneshet Gelaye

Megbaru Alemu Abate

Heven Sime

Henok Hailgiorgis

Bokretsion Gidey

Mebrahtom Haile

Gudissa Assefa

Worku Bekele

Habtamu Belay

Jonathan B Parr

Geremew Tasew

Hussein Mohammed

Ashenafi Assefa

Affiliations

Soon will be listed here.

Abstract

Background: Early case detection and prompt treatment are important malaria control and elimination strategies. However, the emergence and rapid spread of drug-resistant strains present a major challenge. This study reports the first therapeutic efficacy profile of pyronaridine-artesunate against uncomplicated Plasmodium falciparum in Northwest Ethiopia.

Methods: This single-arm prospective study with 42-day follow-up period was conducted from March to May 2021 at Hamusit Health Centre using the World Health Organization (WHO) therapeutic efficacy study protocol. A total of 90 adults ages 18 and older with uncomplicated falciparum malaria consented and were enrolled in the study. A standard single-dose regimen of pyronaridine-artesunate was administered daily for 3 days, and clinical and parasitological outcomes were assessed over 42 days of follow-up. Thick and thin blood films were prepared from capillary blood and examined using light microscopy. Haemoglobin was measured and dried blood spots were collected on day 0 and on the day of failure.

Results: Out of 90 patients, 86/90 (95.6%) completed the 42-day follow-up study period. The overall PCR-corrected cure rate (adequate clinical and parasitological response) was very high at 86/87 (98.9%) (95% CI: 92.2-99.8%) with no serious adverse events. The parasite clearance rate was high with fast resolution of clinical symptoms; 86/90 (95.6%) and 100% of the study participants cleared parasitaemia and fever on day 3, respectively.

Conclusion: Pyronaridine-artesunate was highly efficacious and safe against uncomplicated P. falciparum in this study population.

References

Rueangweerayut R, Phyo A, Uthaisin C, Poravuth Y, Binh T, Tinto H . Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. N Engl J Med. 2012; 366(14):1298-309. DOI: 10.1056/NEJMoa1007125. View

Schrader F, Barho M, Steiner I, Ortmann R, Schlitzer M . The antimalarial pipeline--an update. Int J Med Microbiol. 2012; 302(4-5):165-71. DOI: 10.1016/j.ijmm.2012.07.009. View

Quang Bui P, Hong Huynh Q, Tran D, Le D, Nguyen T, Van Truong H . Pyronaridine-artesunate Efficacy and Safety in Uncomplicated Plasmodium falciparum Malaria in Areas of Artemisinin-resistant Falciparum in Viet Nam (2017-2018). Clin Infect Dis. 2019; 70(10):2187-2195. DOI: 10.1093/cid/ciz580. View

Rehman K, Lotsch F, Kremsner P, Ramharter M . Haemolysis associated with the treatment of malaria with artemisinin derivatives: a systematic review of current evidence. Int J Infect Dis. 2014; 29:268-73. DOI: 10.1016/j.ijid.2014.09.007. View

Roth J, Sawa P, Makio N, Omweri G, Osoti V, Okach S . Pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial. Malar J. 2018; 17(1):199. PMC: 5952621. DOI: 10.1186/s12936-018-2340-3. View

Lutete G, Mombo-Ngoma G, Assi S, Bigoga J, Koukouikila-Koussounda F, Ntamabyaliro N . Pyronaridine-artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: A single-arm, open-label, cohort event monitoring study. PLoS Med. 2021; 18(6):e1003669. PMC: 8205155. DOI: 10.1371/journal.pmed.1003669. View

Degefa T, Zeynudin A, Godesso A, Michael Y, Eba K, Zemene E . Malaria incidence and assessment of entomological indices among resettled communities in Ethiopia: a longitudinal study. Malar J. 2015; 14:24. PMC: 4318213. DOI: 10.1186/s12936-014-0532-z. View

Gallo V, Skorokhod O, Schwarzer E, Arese P . Simultaneous determination of phagocytosis of Plasmodium falciparum-parasitized and non-parasitized red blood cells by flow cytometry. Malar J. 2012; 11:428. PMC: 3546840. DOI: 10.1186/1475-2875-11-428. View

White N . Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother. 1997; 41(7):1413-22. PMC: 163932. DOI: 10.1128/AAC.41.7.1413. View

10.

Bosman P, Stassijns J, Nackers F, Canier L, Kim N, Khim S . Plasmodium prevalence and artemisinin-resistant falciparum malaria in Preah Vihear Province, Cambodia: a cross-sectional population-based study. Malar J. 2014; 13:394. PMC: 4200124. DOI: 10.1186/1475-2875-13-394. View

11.

Valecha N, Srivastava P, Mohanty S, Mittra P, Sharma S, Tyagi P . Therapeutic efficacy of artemether-lumefantrine in uncomplicated falciparum malaria in India. Malar J. 2009; 8:107. PMC: 2693515. DOI: 10.1186/1475-2875-8-107. View

12.

Clark R, Brannen K, Sanders J, Hoberman A . Artesunate and artelinic acid: association of embryotoxicity, reticulocytopenia, and delayed stimulation of hematopoiesis in pregnant rats. Birth Defects Res B Dev Reprod Toxicol. 2011; 92(1):52-68. DOI: 10.1002/bdrb.20282. View

13.

Tshefu A, Gaye O, Kayentao K, Thompson R, Bhatt K, Sesay S . Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet. 2010; 375(9724):1457-67. DOI: 10.1016/S0140-6736(10)60322-4. View

14.

Croft S, Duparc S, Arbe-Barnes S, Craft J, Shin C, Fleckenstein L . Review of pyronaridine anti-malarial properties and product characteristics. Malar J. 2012; 11:270. PMC: 3483207. DOI: 10.1186/1475-2875-11-270. View

15.

Leang R, Mairet-Khedim M, Chea H, Huy R, Khim N, Mey Bouth D . Efficacy and Safety of Pyronaridine-Artesunate plus Single-Dose Primaquine for Treatment of Uncomplicated Malaria in Eastern Cambodia. Antimicrob Agents Chemother. 2019; 63(3). PMC: 6395891. DOI: 10.1128/AAC.02242-18. View

16.

Hoshen M, Na-Bangchang K, Stein W, Ginsburg H . Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of 'dormancy', a partial cytostatic effect of the drug, and its implication for treatment regimens. Parasitology. 2000; 121 ( Pt 3):237-46. DOI: 10.1017/s0031182099006332. View

17.

Poravuth Y, Socheat D, Rueangweerayut R, Uthaisin C, Phyo A, Valecha N . Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS One. 2011; 6(1):e14501. PMC: 3022577. DOI: 10.1371/journal.pone.0014501. View

18.

Gray A, Arguin P, Hamed K . Surveillance for the safety and effectiveness of artemether-lumefantrine in patients with uncomplicated Plasmodium falciparum malaria in the USA: a descriptive analysis. Malar J. 2015; 14:349. PMC: 4573675. DOI: 10.1186/s12936-015-0881-2. View

19.

Garratty G . Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010; 24(4-5):143-50. DOI: 10.1016/j.blre.2010.06.004. View

20.

Leang R, Canavati S, Khim N, Vestergaard L, Fuhrer I, Kim S . Efficacy and Safety of Pyronaridine-Artesunate for Treatment of Uncomplicated Plasmodium falciparum Malaria in Western Cambodia. Antimicrob Agents Chemother. 2016; 60(7):3884-90. PMC: 4914696. DOI: 10.1128/AAC.00039-16. View